Core Insights - Chart Industries reported $1.08 billion in revenue for Q2 2025, a year-over-year increase of 4% and an EPS of $2.59 compared to $2.18 a year ago, but fell short of Zacks Consensus Estimates for both revenue and EPS [1] Financial Performance - Revenue of $1.08 billion represents a surprise of -3.22% against the Zacks Consensus Estimate of $1.12 billion [1] - EPS of $2.59 was below the consensus estimate of $2.62, resulting in an EPS surprise of -1.15% [1] Key Metrics - Total backlog reached $5.54 billion, exceeding the average estimate of $5.24 billion [4] - Backlog for Cryo Tank Solutions was $317.6 million, surpassing the average estimate of $301.82 million [4] - Backlog for Heat Transfer Systems was $2.01 billion, slightly below the average estimate of $2.07 billion [4] - Backlog for Specialty Products was $2.4 billion, exceeding the average estimate of $2.16 billion [4] - Backlog for Repair, Service & Leasing was $801.8 million, above the average estimate of $709.92 million [4] Orders and Sales - Orders for Heat Transfer Systems totaled $271.2 million, below the average estimate of $294.7 million [4] - Orders for Specialty Products were $663.3 million, significantly above the average estimate of $440.99 million [4] - Orders for Repair, Service & Leasing reached $406.1 million, exceeding the average estimate of $324.15 million [4] - Sales for Cryo Tank Solutions were $155.9 million, below the average estimate of $162.74 million, reflecting a year-over-year decline of -5.8% [4] - Sales for Repair, Service & Leasing were $338.2 million, slightly below the average estimate of $340.69 million, with a year-over-year decline of -6.2% [4] - Sales for Specialty Products were $292.9 million, below the average estimate of $331.27 million, but showed a year-over-year increase of +5.5% [4] - Sales for Heat Transfer Systems were $295.3 million, exceeding the average estimate of $277.49 million, with a year-over-year increase of +24.8% [4] Stock Performance - Shares of Chart Industries have returned +4.3% over the past month, outperforming the Zacks S&P 500 composite's +3.6% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - Incyte reported $1.22 billion in revenue for Q2 2025, a 16.5% year-over-year increase, with an EPS of $1.57 compared to -$1.82 a year ago, exceeding Zacks Consensus Estimates for both revenue and EPS [1] - The company’s revenue and EPS surprises were +5.56% and +12.95% respectively, indicating stronger performance than analysts anticipated [1] Revenue Breakdown - Product royalty revenues reached $151.12 million, surpassing the estimated $145.98 million, reflecting a 10.2% increase year-over-year [4] - Net product revenues for Iclusig were $32.73 million, exceeding the $28.99 million estimate, marking a 21.8% year-over-year growth [4] - Total net product revenues amounted to $1.06 billion, above the $985.29 million estimate, showing a 16.9% increase year-over-year [4] - Net product revenues for Pemazyre were $22.19 million, compared to the $20.24 million estimate, representing a 9.5% year-over-year change [4] - Net product revenues for Minjuvi/Monjuvi were $31.13 million, slightly below the $34.25 million estimate, with a minimal year-over-year change of 0.1% [4] - Net product revenues for Opzelura reached $164.5 million, exceeding the $148.56 million estimate, reflecting a significant 35.2% year-over-year increase [4] - Net product revenues for Jakafi were $763.79 million, surpassing the $744.1 million estimate, with an 8.2% year-over-year growth [4] - Net product revenues for Zynyz were $8.92 million, significantly above the $2.73 million estimate, indicating a remarkable 1270.4% year-over-year increase [4] - Royalty revenues for Olumiant were $33.48 million, slightly below the $33.57 million estimate, with a 5.6% year-over-year increase [4] - Royalty revenues for Tabrecta were $6.63 million, below the $6.88 million estimate, reflecting a 25.2% year-over-year increase [4] - Royalty revenues for Jakavi were $109.71 million, exceeding the $103.35 million estimate, with a 10.5% year-over-year change [4] - Net product revenues for Niktimvo were $36.15 million, significantly above the $20.33 million estimate [4] Stock Performance - Incyte's shares returned +3% over the past month, compared to the Zacks S&P 500 composite's +3.6% change, indicating a performance in line with the broader market [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the market in the near term [3]

Core Insights - GMS reported revenue of $1.33 billion for the quarter ended April 2025, a year-over-year decline of 5.6% and an EPS of $1.29 compared to $1.93 a year ago, indicating a significant drop in profitability [1] - The revenue exceeded the Zacks Consensus Estimate of $1.3 billion by 2.81%, while the EPS surpassed the consensus estimate of $1.15 by 12.17% [1] Performance Metrics - GMS shares have returned -2.7% over the past month, contrasting with the Zacks S&P 500 composite's +0.6% change, suggesting underperformance relative to the broader market [3] - The company holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near term [3] Organic Net Sales Analysis - Organic net sales for Wallboard decreased by 12.5%, better than the estimated decline of 15.3% [4] - Organic net sales for Ceilings increased by 2.9%, compared to an estimated decline of 0.9% [4] - Overall organic net sales fell by 9.7%, outperforming the average estimate of a 11.5% decline [4] - Organic net sales for Other products/Complementary products decreased by 7.3%, worse than the estimated decline of 4.1% [4] - Organic net sales for Steel framing dropped by 17.9%, better than the estimated decline of 23.4% [4]

Core Insights - Target reported revenue of $23.85 billion for the quarter ended April 2025, a decrease of 2.8% year-over-year, and EPS of $1.30, down from $2.03 in the same quarter last year [1] - The revenue fell short of the Zacks Consensus Estimate of $24.23 billion, resulting in a surprise of -1.58%, while the EPS also missed the consensus estimate of $1.62 by -19.75% [1] Financial Performance - Comparable store sales decreased by 3.8%, compared to an estimated decline of 1.9% by analysts [4] - Total number of stores was 1,981, slightly below the average estimate of 1,983 [4] - Total retail square footage was 248.66 million square feet, compared to the average estimate of 249.22 million square feet [4] - Digitally originated comparable sales increased by 4.7%, falling short of the average estimate of 8.3% [4] - Total revenue from sales was $23.85 billion, compared to the average estimate of $24.09 billion, reflecting a year-over-year change of -1.2% [4] Market Performance - Target's shares returned +4.3% over the past month, underperforming the Zacks S&P 500 composite's +12.7% change [3] - The stock currently holds a Zacks Rank 5 (Strong Sell), indicating potential underperformance relative to the broader market in the near term [3]

Core Insights - Henry Schein reported $3.17 billion in revenue for Q1 2025, a slight year-over-year decline of 0.1% [1] - The EPS for the quarter was $1.15, up from $1.10 a year ago, indicating a positive trend in earnings [1] - The revenue fell short of the Zacks Consensus Estimate of $3.23 billion by 1.84%, while the EPS exceeded the consensus estimate of $1.11 by 3.60% [1] Revenue Performance - Geographic Revenue from International Dental Equipment was $197 million, below the average estimate of $209.20 million [4] - U.S. Distribution Revenue for Dental Equipment was $187 million, significantly lower than the estimated $232.79 million, reflecting a 25.4% decline year-over-year [4] - International Dental Merchandise revenue was $594 million, also below the estimate of $608.26 million [4] - U.S. Distribution Medical revenue was $1.03 billion, slightly above the estimate of $1.01 billion, showing a year-over-year increase of 1.6% [4] - International Dental revenue was $798 million, under the estimate of $824.47 million, with a year-over-year decline of 1.6% [4] - U.S. Distribution Dental Merchandise revenue was $591 million, exceeding the estimate of $569.68 million [4] - Global Specialty Products net sales were $367 million, slightly above the average estimate of $364.59 million [4] Stock Performance - Henry Schein's shares returned -0.3% over the past month, contrasting with the Zacks S&P 500 composite's +0.4% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]